To evaluate glycemic outcomes in youth (aged 13–25 years) with type 1 diabetes and high-risk glycemic control (HbA1c ≥8.5% [69 mmol/mol]) on multiple daily injection (MDI) therapy after transitioning to advanced hybrid closed loop (AHCL) therapy.
This prospective, 3-month, single-arm, dual-center study enrolled 20 participants, and all completed the study.
HbA1c decreased from 10.5 ± 2.1% (91.2 ± 22.8 mmol/mol) at baseline to 7.6 ± 1.1% (59.7 ± 11.9 mmol/mol), and time spent in target range 70–180 mg/dL (3.9–10.0 mmol/L) increased from 27.6 ± 13.2% at baseline to 66.5 ± 9.8% after 3 months of AHCL. Two episodes of diabetic ketoacidosis attributed to infusion set failure occurred.
AHCL has the potential to improve suboptimal glycemia in youth with type 1 diabetes previously on MDI therapy.
Clinical trial reg. no. ACTRN12621000556842, www.anzctr.org.au
This article contains supplementary material online at https://doi.org/10.2337/figshare.21785207.